MONTREAL, QUEBEC , April 25, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the “Meeting”).

Election of Directors

All director nominees set out in the Management Information Circular dated March 22, 2024, were elected as directors, to serve until the next meeting of shareholders of the Company or until their successors are elected or appointed.The results of the vote for those elected as directors are as follows:

NomineesVotes ForVotes Against
 Number of Shares%Number of Shares%
Steve Saviuk51,134,10491.984,461,3408.02
Richard MacKay51,101,75491.924,493,6908.08
Marc Léger51,135,10491.984,460,3408.02
Richard Lajoie54,233,97597.551,361,4692.45
Robert Raich55,232,97599.35362,4690.65
Charles Bisaillon47,810,53586.007,784,90914
Al Moghaddam55,232,97599.35362,4690.65

Appointment of the auditor

The Company’s shareholders also appointed Audacie Inc. as auditor of the Company for the ensuing year at a remuneration to be fixed by the directors.The results of the vote for the appointment of Audacie Inc. as the auditor for Valeo are as follows:

Votes ForVotes Withheld
 Number of Shares%Number of Shares%

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit and follow us on LinkedIn and Twitter.

Forward Looking Statements

Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook.                     

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: reliance on third-party suppliers and manufacturers, the availability of additional funding, common risks for pharmaceutical products, including product liability claims, insurance and recalls, registration risks in certain jurisdictions, the inability to implement Valeo’s strategy to grow the business, dependence on key management personnel and executives, competition, currency fluctuations and the risks, uncertainties and other factors contained in the section entitled “Risk Factors” in Valeo’s annual information form dated January 29, 2024, a copy of which is available on Valeo’s Sedar+ profile at

Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect Valeo’s business, or if Valeo’s estimates or assumptions turn out to be inaccurate. Valeo undertakes no obligation to update publicly, or otherwise revise, any forward-looking statements, whether as a result of new information or future events or otherwise, except as may be required by law. If Valeo does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law.

For more information:

Steve Saviuk



[email protected]


Frederic Dumais

Director, Communications and Investor Relations


[email protected]